Subscribe To
syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
syfovre reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sha...
November 4, 2023, 5:37 pm
Apellis (apls) q3 loss wider than expected, syfovre drives sales
Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, ...
November 2, 2023, 12:47 pm
Apellis pharmaceuticals reports third quarter 2023 financial results
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for syfovre® ...
November 1, 2023, 11:05 am
Apellis announces preliminary u.s. net revenues of approximately $74 million for syfovre® (pegcetacoplan injection) in the third quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting i...
October 5, 2023, 11:00 am
Lifshitz law pllc announces investigations of apellis pharmaceutics, inc. (nasdaq: apls), rtx corp. (nyse: rtx), live nation entertainment, inc. (nyse: lyv), and keycorp (nyse: key)
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible sec...
September 2, 2023, 11:00 pm
Apellis (apls) dips on layoffs amid syfovre safety issues
Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn....
August 30, 2023, 9:46 am
Biopharmaceutical stock soars on positive drug update
The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue w...
August 23, 2023, 11:22 am
Why is apellis pharmaceuticals (apls) stock up 23% today?
Apellis Pharmaceuticals (NASDAQ: APLS ) stock is on the rise Wednesday after the biopharmaceutical company announced an update on injection kits. The...
August 23, 2023, 8:28 am
Apellis pharmaceuticals stock jumps on safety review update
Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 30% in Wednesday's premarket after last night updating investors on an ongoing safety review of ...
August 23, 2023, 7:52 am
Apellis (apls) focuses on empaveli to fuel its growth
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, ...
August 15, 2023, 10:55 am
Apellis (apls) q2 earnings top, syfovre sales boost revenues
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding ...
August 1, 2023, 11:55 am
syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy (ga)
syfovre reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected s...
July 30, 2023, 5:00 pm
Apellis provides update on review of rare safety events with syfovre® (pegcetacoplan injection) for geographic atrophy
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive...
July 29, 2023, 6:52 pm
First-to-market edge for apellis’s syfovre in geographic atrophy diminished in the face of an unexpected safety signal
Prospects for syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflam...
July 28, 2023, 4:26 pm
Apellis (apls) plunges on safety issues with eye treatment
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with ...
July 19, 2023, 12:52 pm
Apellis: exercise caution in response to safety signal (rating downgrade)
Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, ...
July 18, 2023, 10:08 am
Apellis (apls) q1 earnings miss, empaveli & syfovre fuel growth
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and syfovre...
May 5, 2023, 10:40 am
Top-notch biotech apellis soars after new drug obliterates sales views
Apellis' new eye drug, syfovre, crushed expectations in its first quarter post launch, putting APLS sto...
May 5, 2023, 9:36 am
Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy
Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the loss of retinal pigmented epithelial and photorece...
April 23, 2023, 10:05 pm
Apellis (apls) stock up 50% in three months: here's why?
Apellis (APLS) stock rises 50% in the past three months owing to the approval of syfovre (pegcetacoplan...
April 11, 2023, 12:16 pm